about
Identification of a melanoma antigen, PRAME, as a BCR/ABL-inducible geneThe beta-amyloid precursor protein APP is tyrosine-phosphorylated in cells expressing a constitutively active form of the Abl protoncogeneJAK2 V617F in myeloid disorders: what do we know now, and where are we headed?Signaling pathways activated by oncogenic forms of Abl tyrosine kinase.Chronic myelogenous leukemia. Curable with early diagnosis and treatment.Summary of 615 patients of chronic myeloid leukemia in Shanghai from 2001 to 2006Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNKChronic myelogenous leukaemia--new therapeutic principles.Understanding the economic value of molecular diagnostic tests: case studies and lessons learned.Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL(1).ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.Management of molecular-targeted therapy for chronic myelogenous leukemia.Dasatinib: the emerging evidence of its potential in the treatment of chronic myeloid leukemia.High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses.Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications.A 54-Year-Old Woman with Donor Cell Origin of Multiple Myeloma after Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of CML.Global effects of BCR/ABL and TEL/PDGFRbeta expression on the proteome and phosphoproteome: identification of the Rho pathway as a target of BCR/ABL.Adenosine monophosphate deaminase 3 activation shortens erythrocyte half-life and provides malaria resistance in mice.Polarized distribution of Bcr-Abl in migrating myeloid cells and co-localization of Bcr-Abl and its target proteins."Preleukemic or smoldering" chronic myelogenous leukemia (CML):BCR-ABL1 positive: A brief case report.Targeted superantigens for immunotherapy of haematopoietic tumours.Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study.A model of oscillatory blood cell counts in chronic myelogenous leukaemia.Molecular beacon-based fluorescence biosensor for the detection of gene fragment and PCR amplification products related to chronic myelogenous leukemia.The impact of introducing tyrosine kinase inhibitors on chronic myeloid leukemia survival: a population-based study
P2860
Q28145180-C4D8A0AD-FB15-44BF-AECD-1752035D74F0Q28208729-2B7948DF-6E50-4970-9FFD-298858E69251Q33341856-9DAB60C1-243C-4DD2-AA6B-4944D3B13A44Q33663180-E562C570-8DD6-4993-AF09-B4F3BE777CA7Q33736783-4F18B32C-C1C7-419F-8DF8-D1B862AAA35DQ33748871-F3692427-9B52-4CB6-8A71-05E7E0E5C732Q33810952-258ED09E-A692-4D3F-B8E5-D092C163986FQ34308917-A5AE6312-AC41-45CE-9AC1-4C997B6C6B34Q34608705-0BB444D2-5C04-49C5-A9E9-33170BBE3F22Q35102183-369341EE-42B2-4F41-AE3A-C8F5AA272678Q35171274-BE1C263E-96A5-46B4-AFDA-084853DFC4D7Q35203394-A5D6234A-3FE9-4362-9A98-9B82D6B941E2Q35876347-5CA2DDFB-88F7-4130-9794-E3C1F7699E5AQ37163734-B3CBBF8C-4CFD-4DBB-8C6C-59C020341BE5Q37797981-1F94E519-75BA-4D62-A3A3-E285816563F1Q38737985-20823745-5EF3-4274-9332-DE168E9CF1BDQ40486959-C2D4DD07-70A3-4B3C-9AA5-88CECF95189DQ40597359-21A4B8DA-C420-41E4-831D-C622A5415F1EQ42819449-D31E8D5A-1BB1-4AA5-AB0A-EBF56AFEBC69Q43120248-9DAAE11A-8F57-4E83-A916-99198F907891Q47686578-7188E22D-A67D-4BCA-9647-A5DC24D72E83Q47767989-07FF8F21-4ACD-4235-B3F1-B3E802DD0FB5Q50539303-8597C1D4-247A-4E0F-9A9C-031CFFCBCA08Q54343040-CDD67503-C25A-4D8C-9CBB-12BEA2DCDDE0Q58605235-8A9E1D77-947E-4EA6-90B8-14B17D3E8C9B
P2860
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Chronic myelogenous leukemia: a review.
@en
type
label
Chronic myelogenous leukemia: a review.
@en
prefLabel
Chronic myelogenous leukemia: a review.
@en
P2093
P1476
Chronic myelogenous leukemia: a review.
@en
P2093
P304
P356
10.1016/S0002-9343(96)00061-7
P407
P577
1996-05-01T00:00:00Z